JMDC Inc. (JP:4483)
:4483
Want to see JP:4483 full AI Analyst Report?
Top Page
JMDC Inc.
(4483)
Select Model
Select Model
Rating:60Neutral
Price Target:
¥2,958.00
▼(-37.02% Downside)
Action:Reiterated
Date:05/14/26
The score is anchored by strong, durable margins but held back by decelerating growth, rising leverage, and uneven cash-flow consistency. Technicals are the biggest near-term negative, with the stock in a pronounced downtrend and very weak momentum. Valuation is only moderately supportive given the ~31x P/E and low dividend yield.
Positive Factors
High and resilient margins
Persistently strong gross and operating margins indicate durable unit economics from data licensing and analytics. High margins provide internal funding for dataset expansion, R&D and sales, and create resilience versus cyclical revenue swings, supporting long-term profitability and reinvestment.
Negative Factors
Revenue growth has decelerated
A meaningful slowdown to low-single-digit TTM growth limits the company’s ability to convert strong margins into faster earnings expansion. Slower top-line momentum strains scale economics over time, making it harder to finance new datasets, sales expansion, or margin-enhancing investments.
Read all positive and negative factors
Positive Factors
Negative Factors
High and resilient margins
Persistently strong gross and operating margins indicate durable unit economics from data licensing and analytics. High margins provide internal funding for dataset expansion, R&D and sales, and create resilience versus cyclical revenue swings, supporting long-term profitability and reinvestment.
Read all positive factors
JMDC Inc. (4483) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥175.90B
Dividend Yield0.43%
Average Volume (3M)283.60K
Price to Earnings (P/E)31.3
Beta (1Y)0.73
Revenue Growth20.95%
EPS Growth13.39%
CountryJP
Employees1,773
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)103.42
Shares Outstanding65,439,810
10 Day Avg. Volume398,940
30 Day Avg. Volume283,596
Financial Highlights & Ratios
PEG Ratio2.34
Price to Book (P/B)2.53
Price to Sales (P/S)4.20
P/FCF Ratio26.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥4,264.00Price Target Upside-9.22% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)143.58
Revenue Forecast (FY)¥60.48B
JMDC Inc. Business Overview & Revenue Model
Company Description
JMDC Inc. (4483) is a leading company in the healthcare sector, primarily focused on providing data analytics and technology solutions. The company specializes in health data management, offering services that include healthcare big data analysis,...
How the Company Makes Money
JMDC makes money primarily by monetizing its healthcare data assets and analytics capabilities through (1) data platform and data provision services and (2) analytics/solution services delivered to enterprises. A key revenue driver is providing in...
JMDC Inc. Financial Statement Overview
Summary
Income Statement
83
Very Positive
Balance Sheet
74
Positive
Cash Flow
62
Positive
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 50.46B | 41.72B | 30.57B | 27.81B | 21.81B |
| Gross Profit | 27.69B | 22.47B | 17.10B | 14.77B | 11.63B |
| EBITDA | 13.18B | 10.93B | 8.80B | 7.73B | 6.45B |
| Net Income | 6.76B | 5.96B | 3.32B | 4.27B | 3.25B |
Balance Sheet | |||||
| Total Assets | 158.54B | 143.02B | 122.45B | 98.57B | 62.05B |
| Cash, Cash Equivalents and Short-Term Investments | 28.95B | 32.18B | 14.47B | 22.78B | 13.19B |
| Total Debt | 52.05B | 46.89B | 37.83B | 20.40B | 17.80B |
| Total Liabilities | 74.35B | 64.54B | 51.76B | 34.04B | 30.89B |
| Stockholders Equity | 83.68B | 78.02B | 70.59B | 64.54B | 31.17B |
Cash Flow | |||||
| Free Cash Flow | 8.01B | 12.57B | -910.00M | 3.24B | 3.36B |
| Operating Cash Flow | 8.59B | 14.69B | -17.00M | 4.06B | 3.81B |
| Investing Cash Flow | -10.56B | -3.47B | -24.86B | -22.77B | -8.10B |
| Financing Cash Flow | -1.26B | 6.48B | 16.58B | 28.30B | -2.41B |
JMDC Inc. Technical Analysis
Neutral
4697.00
Price Trends
3594.83
Positive
3704.34
Negative
3997.59
Negative
Market Momentum
31.11
Negative
52.76
Neutral
74.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4483, the sentiment is Neutral. The current price of 4697 is above the 20-day moving average (MA) of 3424.88, above the 50-day MA of 3594.83, and above the 200-day MA of 3997.59, indicating a neutral trend. The MACD of 31.11 indicates Negative momentum. The RSI at 52.76 is Neutral, neither overbought nor oversold. The STOCH value of 74.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4483.
JMDC Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ¥31.82B | 6.80 | ― | 2.58% | 5.70% | 35.98% | |
68 Neutral | ¥920.15B | 36.11 | 12.15% | 1.01% | 23.33% | 21.65% | |
60 Neutral | ¥175.90B | 31.32 | ― | 0.43% | 20.95% | 13.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥71.00B | -232.45 | 5.76% | ― | 23.30% | -56.05% | |
44 Neutral | ¥2.41B | -4.65 | ― | ― | 18.86% | 38.80% |
* Healthcare Sector Average
JP:4483
JMDC Inc.
2,688.00
-438.79
-14.03%
JP:2413
M3
1,355.00
-569.80
-29.60%
JP:4480
Medley
2,169.00
-1,031.00
-32.22%
JP:4438
Welby Inc.
286.00
-63.00
-18.05%
JP:9438
MTI Ltd.
590.00
-234.65
-28.45%
JMDC Inc. Corporate Events
JMDC Raises Year-End Dividend, Keeps Future Payout Outlook Undecided
May 8, 2026
JMDC Inc. has approved a year-end dividend of ¥18 per share for the fiscal year ended March 31, 2026, up from ¥16 the previous year, bringing total dividends to ¥1,177 million, with payment scheduled to begin on June 8, 2026. The co...
JMDC boosts revenue and dividend as profit slips, eyes further growth in FY2027
May 8, 2026
JMDC reported consolidated revenue of ¥50.46 billion for the year to March 31, 2026, up 20.9% as it expanded its healthcare data and analytics operations, with operating profit rising 20.7% to ¥10.52 billion and EBITDA improving to ¥...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.